Jilani, Sameeha
Saco, Justin D.
Mugarza, Edurne
Pujol-Morcillo, Aleida
Chokry, Jeffrey
Ng, Clement
Abril-Rodriguez, Gabriel
Berger-Manerio, David
Pant, Ami
Hu, Jane
Gupta, Rubi
Vega-Crespo, Agustin
Baselga-Carretero, Ignacio
Chen, Jia M. http://orcid.org/0000-0003-3992-9143
Shin, Daniel Sanghoon
Scumpia, Philip http://orcid.org/0000-0002-2563-2042
Radu, Roxana A. http://orcid.org/0000-0002-5064-6403
Chen, Yvonne
Ribas, Antoni http://orcid.org/0000-0003-3669-8458
Puig-Saus, Cristina http://orcid.org/0000-0002-3014-3649
Funding for this research was provided by:
United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (W81XWH2110839)
California Institute for Regenerative Medicine (12258)
Melanoma Research Alliance (824855)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35 CA197633)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (P01 CA244118)
Article History
Received: 17 August 2023
Accepted: 18 January 2024
First Online: 9 February 2024
Competing interests
: A.R. has received honoraria from consulting with Amgen, Bristol-Myers Squibb, Chugai, Dynavax, Genentech, Merck, Nektar, Novartis, Roche, and Sanofi, is or has been a member of the scientific advisory board and holds stock in Advaxis, Arcus Biosciences, Bioncotech Therapeutics, Compugen, CytomX, Five Prime, RAPT, ImaginAb, Isoplexis, Kite-Gilead, Lutris Pharma, Merus, PACT Pharma, Rgenix and Tango Therapeutics. A.R. is a co-founder of PACT Pharma, a member of the Board of Directors, and holds founder stock. Y.Y.C., A.R., and C.P.-S. are founders of, hold equity in, are members of the Scientific Advisory Board, and receive consulting fees from ImmPACT Bio. Y.Y.C. is a member of the scientific advisory board and holds equity in Catamaran Bio, Notch Therapeutics, Pluto Immunotherapeutics, Prime Medicine, Sonoma Biotherapeutics, and Waypoint Bio. She has consulted for Novartis and Gritstone Bio.UCLA has filed Patent applications on aspects of the described work, entitled “Chimeric Antigen Receptors and Related Methods and Compositions for the Treatment of Cancer” (WO2021046432A1). No potential competing interests were disclosed by the other authors.